Skip to content

Assessment of safety and efficacy of product

To evaluate the in-vivo efficacy and safety of hair care formulation in terms of reduction in hair fall effect on human subjects - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064647
Enrollment
36
Registered
2024-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L659- Nonscarring hair loss, unspecified

Interventions

Intervention1: Regime with Beauty Garage Scalp Sense Soothing Shampoo, Beauty Garage Scalp Sense Intense Scalp Clear Treatment, Beauty Garage Scalp Sense Dandruff Defence Scalp Vaccine Treatment Condi

Sponsors

BEAUTY GARAGE INDIA PVT. LTD.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Asian Indian humans subjects. 2.Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup) 3.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….) 4.Having oily scalp and moderate to severe hair fall

Exclusion criteria

Exclusion criteria: 1.Being pregnant or breastfeeding or having stopped to breastfeed in the past three months. 2.Having refused to give his/her assent by not signing the consent form. 3.Taking part in another study liable to interfere with this study. 4.Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area. 5.Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months) 6.Having a progressive asthma (either under treatment or last fit in the last 2 years) 7.Being epileptic 8.Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 9.Having cutaneous hypersensitivity 10.Following a chronic or intermittent medicinal treatment comprising any of the following products : aspirin-based products, anti-inflammatories, anti-histamines, anti-coagulants, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 11.Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months 12.Having changed her cosmetic habits except those mentioned in protocol in the 7 days preceding the start of the study on the studied anatomic unit

Design outcomes

Primary

MeasureTime frame
Reduction in hair fall, SafetyTimepoint: Baseline, 14 days, 28 days

Secondary

MeasureTime frame
NilTimepoint: NA

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

raji@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026